ReviewBMC neurology2016
Paraproteinemic neuropathy: a practical review.
Review in BMC neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 70 citations in OpenAlex.
- [The nervous system and communication: polyneuropathy and the role of the peripheral nervous system].Zeitschrift fur Gerontologie und Geriatrie · 2026Review
- A Case of Advanced Charcot-Marie-Tooth Disease Showing Extreme Lumbosacral Nerve Root Hypertrophy.Cureus · 2026Article
- Thrombosis in Neuromuscular Medicine: Current Evidence, Unmet Needs, and Future Directions.Journal of clinical medicine · 2026Review
- Pathologic and Therapeutic Schwann Cells.Cells · 2025Review
- Blood pressure variability as predictor of cancer therapy-related cardiovascular toxicity in patients with Multiple Myeloma.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Effects of oral steroid sparing immunosuppressive drugs in long term maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy.Pakistan journal of medical sciences · 2024Article
- Neuralgic Amyotrophy and Hourglass Nerve Constriction/Nerve Torsion: Two Sides of the Same Coin? A Clinical Review.Brain sciences · 2024Review
- Review
- Immunoglobulin M Monoclonal Gammopathies of Clinical Significance.Frontiers in oncology · 2022Review
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Association With Concomitant Diseases: Identification and Management.Frontiers in immunology · 2022Review
- Article
- Treatment Approaches for Atypical CIDP.Frontiers in neurology · 2021Review
- Pain in the Cancer Survivor.Cancer treatment and research · 2021Article
- Response of multifocal acquired demyelinating sensorimotor neuropathy associated with atypical chronic lymphocytic leukemia to rituximab therapy.Blood research · 2020Article
- Immunoglobulin M Paraproteinaemias.Cancers · 2020Review
- Distinctive patterns of peripheral neuropathy across the spectrum of plasma cell disorders.Scientific reports · 2019Article
- Resistant type II cryoglobulinaemic vasculitis successfully treated with bortezomib in a patient with SLE.BMJ case reports · 2019Article
- Peripheral Demyelinating Diseases: From Biology to Translational Medicine.Frontiers in neurology · 2019Review
- Article
- Multiple Myeloma of the Central Nervous System: 13 Cases and Review of the Literature.Journal of oncology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The term paraproteinemic neuropathy describes a heterogeneous set of neuropathies characterized by the presence of homogeneous immunoglobulin in the serum. An abnormal clonal proliferation of B-lymphocytes or plasma cells, which may or may not occur in the context of a hematologic malignancy, produces the immunoglobulins in excess. If malignancy is identified, treatment should be targeted to the neoplasm. Most cases, however, occur as monoclonal gammopathy of undetermined significance. Few prospective, randomized, placebo-controlled trials are available to inform the management of paraproteinemic neuropathies. Clinical experience combined with data from smaller, uncontrolled studies provide a basis for recommendations, which depend on the specific clinical setting in which the paraprotein occurs. In this review, we provide a clinically practical approach to diagnosis and management of such patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.